Physician Assistant Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

John Eastman

Physician Assistant Fall River, MA Physician Assistant

NPI 1720608912 CMS profile 10948421

277 Pleasant St, Fall River, MA 02721

Open in the dashboard

General payments

$726

26 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, John Eastman of Fall River, MA is reported in the CMS Open Payments database as having received $726 across 26 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $369 15
2021 General $357 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Eastman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to John Eastman were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year John Eastman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $357 $132 $37–$438 $132
2022 $369 $155 $48–$522 $149
2023 $0 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. Corcept Therapeutics $145 1 payment
  2. Lilly USA, LLC $111 5 payments
  3. Esperion Therapeutics, Inc. $93 1 payment
  4. Antares Pharma, Inc. $66 3 payments
  5. AstraZeneca Pharmaceuticals LP $64 4 payments
  6. Amgen Inc. $50 2 payments
  7. Sanofi-Aventis U.S. LLC $48 2 payments
  8. Novo Nordisk Inc $43 2 payments
  9. Abbott Laboratories $41 2 payments
  10. Xeris Pharmaceuticals, Inc. $21 1 payment
  11. Other $44 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Food and Beverage $726 26 payments
Products named General payments · program years 2021–2022
  1. Korlym $145 1 payment
  2. JARDIANCE $111 5 payments
  3. TRULICITY $111 5 payments
  4. NEXLETOL $93 1 payment
  5. NEXLIZET $93 1 payment
  6. Repatha $50 2 payments
  7. XYOSTED $46 2 payments
  8. Ozempic $43 2 payments
  9. FreeStyle Libre 2 $41 2 payments
  10. RYBELSUS $25 1 payment
  11. Other $173 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

207

Median for Physician Assistant: 241

Drug cost

$10,573

Median for Physician Assistant: $4,110

Branded share of claims

19.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 14 $8,464
Albuterol Sulfate Hfa Albuterol Sulfate Brand 13 $532
Atorvastatin Calcium Generic 19 $301
Levothyroxine Sodium Generic 11 $224
Doxycycline Monohydrate Generic 20 $183
Omeprazole Generic 13 $182
Amlodipine Besylate Generic 21 $160
Losartan Potassium Generic 14 $134
Metoprolol Succinate Generic 12 $114
Hydroxyzine Hcl Generic 16 $112

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$23,334

Of which drugs: $2,277

Medicare patients

201

Average age 71

Services billed

475

109 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 51%
Diabetes 29%
Chronic kidney disease 27%
Ischemic heart disease 24%
Depression 24%
COPD 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 11 11 $1,608

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record